MARK3 Antibodies

Structure of MARK3

MARK3 is a serine/threonine protein kinase with a molecular weight of approximately 90 kDa, and its precise molecular weight varies slightly among different species.

MARK3 is composed of multiple domains, including the N-terminal kinase domain and the C-terminal microtubule binding region, forming a functional spatial conformation through α -helix and β -folding. Its catalytic core contains a conserved ATP-binding site (Gly-X-Gly-X-X-Gly motif) and an activation loop (T-loop), while the C-terminal domain regulates kinase activity through phosphorylation modification. The unique KA1 (kinase-associated 1) domain of this protein is involved in membrane localization. This modular design enables it to coordinate cytoskeletal recombination and polarity establishment.

Fig. 1 Schematic of the effect of MARK3 inducing G2/M phase arrest with CDK1 inhibition.¹

Key structural properties of MARK3:

• Modular kinase domain (N-terminal)
• Unique KA1 domain (C-end)
• Regulating element
• Key functional residues

Functions of MARK3

The core function of the MARK3 gene is to regulate microtubule stability and cell polarity, and it is also involved in a variety of important cellular processes.

The enzyme activity curve of MARK3 exhibits typical biphasic characteristics: it shows Michaelis-Menten kinetics at low substrate concentrations, while it shows allostrucic regulatory properties at high substrate concentrations. This unique dynamic feature enables it to precisely respond to a variety of cellular signals (including phosphorylation modifications and protein interactions), thereby playing the role of a "molecular switch" in processes such as neurodevelopment and tumor metastasis.

Applications of MARK3 and MARK3 Antibody in Literature

1. Wang, Yudan, and Liyuan Guo. "Mark3 a Prognostic Marker for the Endometrial Cancer." Current Oncology 32.3 (2025): 157.https://doi.org/10.3390/curroncol32030157

The article indicates that MARK3 inhibits cell proliferation and migration in endometrial cancer, and its overexpression reduces colony formation and viability of Ishikawa and HEC-1B cells, possibly exerting its effect by regulating the pAKT pathway. Bioinformatics analysis suggests its potential as a prognostic marker and therapeutic target.

2. Machino, Hidenori, et al. "The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma." Communications Biology 5.1 (2022): 39.https://doi.org/10.1038/s42003-021-02992-4

The article indicates that MARK3 is down-regulated in high-grade serous ovarian cancer (HGSOC) and is associated with a poor prognosis. Overexpression of MARK3 can inhibit cancer cell proliferation and angiogenesis, induce G2/M phase arrest through the LKB1-MARK3-CDC25 pathway, and down-regulate AP-1 and Hippo signaling target genes. Metabolic stress inducers targeting this pathway may become potential therapies.

3. Aparicio-Bautista, Diana I., et al. "Interaction between MARK3 (rs11623869), PLCB4 (rs6086746) and GEMIN2 (rs2277458) variants with bone mineral density and serum 25-hidroxivitamin D levels in Mexican Mestizo women." Frontiers in Endocrinology 15 (2024): 1392063.https://doi.org/10.3389/fendo.2024.1392063

Research has found that in Mexican women, the MARK3 gene variation (rs11623869) interacts with PLCB4 and GEMIN2, affecting bone mineral density (BMD) in the hip and femoral neck as well as vitamin D levels. The polygenic risk score (GRS) indicates that the combined effect of the three is significant, which may provide a new target for the early intervention of osteoporosis.

4. Lund, Harald, et al. "MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies." Acta neuropathologica communications 2.1 (2014): 22.https://doi.org/10.1186/2051-5960-2-22

Studies have found that in the hippocampus of patients with Alzheimer's disease (AD), the phosphorylated forms of MARK3 and MARK4 are co-localized with p-tau Ser262 in granular vacuolar denaturates (GVDs), suggesting that neurons may clear overactivated MARK kinases through GVDs, thereby reducing abnormal phosphorylation of tau protein. Slow down the progression of neurodegenerative diseases.

5. Calabrese, Gina M., et al. "Integrating GWAS and co-expression network data identifies bone mineral density genes SPTBN1 and MARK3 and an osteoblast functional module." Cell systems 4.1 (2017): 46-59.https://doi.org/10.1016/j.cels.2016.10.014

Research has found that the MARK3 gene is associated with the pathogenesis of osteoporosis, and its single nucleotide variation (rs11623869) affects bone mineral density (BMD) and vitamin D levels in Mexican women through intergene interactions. This gene may become a new target for the early intervention of osteoporosis.

Creative Biolabs: MARK3 Antibodies for Research

Creative Biolabs specializes in the production of high-quality MARK3 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom MARK3 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our MARK3 antibodies, custom preparations, or technical support, contact us at email.